Quidel (QDEL) Announces FDA Clearance for Its Quidel Molecular Influenza A+B Assay
Tweet
Share
E-mailGet Alerts QDEL Hot Sheet
Join SI Premium – FREE
Quidel Corporation (NASDAQ: QDEL) received 510(k) clearance from the FDA for its "Quidel Molecular" Influenza A+B Assay for the detection of influenza A and B for use with Cepheid's SmartCycler PCR system.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- INmune Bio files for EMA orphan drug status for its RDEB cell therapy
- Summit Therapeutics publishes HARMONi Phase III lung cancer trial data
- Nektar's atopic dermatitis drug data published in The Lancet
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
